Tumor suppressor p53 plays an essential role in protecting cells from malignant transformation by inducing cell cycle arrest and apoptosis. Mutant p53 that is detected in over 50% cases of cancers not only loses its role in suppressing of tumor but also gains oncogenic function. Strategies to convert mutant p53 into wild-type of p53 have been suggested for cancer prevention and treatment, but they face a variety of challenges. Here we report an alternate approach that involves suppression of glucosylceramide synthase (GCS), an enzyme that glycosylates ceramide and blunts its pro-apoptotic activity in cancer cells. Human ovarian cancer cells expressing mutant p53 displayed resistance to apoptosis induced by DNA damage. We found that GCS silencing sensitized these mutant p53 cells to doxorubicin, but did not affect the sensitivity of cells with wild-type p53. GCS silencing increased the levels of phosphorylated p53 and p53-responsive genes including p21 
Introduction
p53 protein is a crucial tumor suppressor in preventing tumorigenesis and tumor progression (1) (2) . As an essential transcription factor, p53 activates the expressions of p21 Waf1/Cip1 , Bax, Puma, FAS and others, and consequently regulates cell cycle arrest and apoptosis to remove abnormal cells (1) (2) . The transcription activity of p53 on p53-responsive genes is sequencespecific, and mainly relies on its DNA-binding domain (DBD, residues 102 to 292) encoded by exon 5 to exon 8 (1) (2) . In normal cells, the p53 is tightly controlled and kept at low level, but DNA damage, oncogenic stress, hypoxia and cellular distress activate p53 by increasing its expression and protein phosphorylation through various kinases (3) (4) . p53 mutants that have been found in approximately 50% cases of solid cancers turn this tumor suppressor into an oncogenic factor (5-6). p53 mutants are mainly located in exon [5] [6] [7] [8] (residue 126-306) of the core domain (6) . Mutant p53 thus loses sequence specific binding to its responsive genes involved in cycle arrest, senescence and apoptosis. Mutant p53 is unable to activate MDM2 and degrades protein through ubiquitination, resulting in mutant protein accumulated in cell nucleus (7) . Mutation of other tumor suppressors often produces truncated 4 conformation (13) (14) (15) ; however, little is known whether p53 expression can be restored in 53-mutant tumors. Gene therapy could not bring an adequate benefit to ovarian cancers with standard chemotherapy (16) , that calls for exploration of new approach, restoring the expression of wild-type p53.
Drug resistance is an outcome of multi-gene interactions, and p53 mutant impedes inducedapoptosis when cancer cells are under chemotherapy. Ceramide is an active sphingolipid and plays critical roles in processing of apoptosis and other cellular functions (17) (18) (19) (20) . Both ceramide and p53 are implicated in DNA-damage induced apoptosis (17) (18) . Loss of ceramide production confers resistance to radiation-induced apoptosis in B-lymphoma and myeloid leukemia cells that express wild-type p53 (21) (22) . Glucosylceramide synthase (GCS) catalyzes ceramide glycosylation, converting ceramide to glucosylceramide. GCS is a limiting enzyme controlling intracellular ceramide and glycosphingolipids (23) . Overexpression of GCS that confers cell resistance to apoptosis (24-25) becomes a potential marker predicting tumor response to chemotherapy and clinical progression (26-27). Inhibition of GCS by gene silencing or tamoxifen leads p53-mutant cancer cells to apoptosis (25, (28) (29) . In the present study, we investigate whether disruption of ceramide glycosylation restores p53-dependent apoptosis in p5-mutant cancer cells. , Bax (Santa Cruz Biotechnology), active caspase-7 (a-Casp7, EMD Chemicals, Gibbstown, NJ) and GCS (1:500 to 1:5000 dilution), respectively, at 4 ºC, overnight. After washing, these blots were incubated with horseradish peroxide-conjugated secondary antibodies, and developed using SuperSignal ® West Pico ECL (Thermo scientific, Rockford, IL), as described previously (34) (35) . Endogenous GAPDH was used as a loading control. The levels of pp53 protein were represented by the ratios of optical densities in pp53 bands normalized against unphosphorylated p53.
Immunocytochemistry
Cells (10,000 cells/chamber) were grown in 4-chamber slides with treatments for 48 hr. After fixation with methanol, cells were blocked with 5% goat serum PBS (block solution) incubated with antibodies against GCS (1:1000) or ceramide (1:500; clone MID 15B4 from Sigma) and pp53 (1:1000) in block solution at 4ºC, overnight. Cellular GCS and pp53 tagged with antibodies were recognized by Alexa Fluor were stained with Hematoxylin and Eosin (H&E) and identified by pathologist. For immunostaining, antigens were retrieved in steaming sodium citrate buffer (10 mM, 0.05% Tween-20, pH 6.0). After blocking, slides were incubated with anti-GCS rabbit serum (1:100) and anti-pp53 mouse primary antibodies at 4°C overnight. Cell nuclei were counterstained with DAPI.
Flow cytometry assay
The analyses were performed, as described previously (29). Cells (5x10 5 cells/100-mm dish) were exposed to doxorubicin (2.5 µM) for 48 hr and harvested with trypsinization and centrifugation. Cells resuspended were incubated with 0.01% propidium iodide (PI) in staining solution (0.1% sodium citrate, 0.3% Triton X-100, 2 mg/ml ribonuclease A) at 4°C for 30 min.
The cells were analyzed using FACSCalibur with CellQuest Pro program (BD Biosciences, San Jose, CA). For each sample, 10,000 events were counted three times and sub-phase G0/G1 was defined as indicative of apoptotic cells in cell cycle histograms.
Tumor xenografts and treatments
All animal experiments were approved by the IACUC, University of Louisiana at Monroe, and were handled in strict accordance with good animal practice as defined by NIH guidelines.
Tumor model was established, as described previously (29, 34) . Athymic nude mice 
Terminal-deoxynucleotide-transferase-mediated dUTP nick end labeling (TUNEL) staining
Apoptotic cells of tumor tissues were detected by measurement of nuclear DNA fragmentation using TUNEL system (Promega), following the manufacturer's instruction, as described previously (29). Briefly, after antigen retrieval, slides were put in 0.2 mg/ml proteinase K in 10 mM Tris-HCl, pH 8.0 for 20 min for digestion and labeled for 90 min with fluorescein-12-dUTP terminal deoxynucleotide transferase reaction mixture at 37°C in a humidified chamber. After mounting with DAPI, the sections were observed.
Statistical analysis
Cell experiments in triplicate were repeated twice. All data represent the mean ± SD. 
Results

Silencing of GCS by MBO-asGCS sensitized mutant p53 cells to doxorubicin
Mutant p53, particularly the deletion is highly associated with poor-response to chemotherapy (10) (11) . NCI/ADR-RES and OVCAR-8 cells are mutant p53 cell lines that dominantly express the p53 with deleted 21-bp and 18-bp within the DNA-binding domain (36-37). NCI/ADR-RES has an additional point mutation, arginine instead of proline at codon 72 of p53 (36). A2780ADR (also named A2780-DX3) cells do not respond to cisplatin-induced p53 activation, even though the mutation has not been determined (32) ( Table 1) . NCI/ADR-RES, OVCAR-8 and A2780ADR display considerable resistance to several anticancer drugs including doxorubicin and cisplatin (31, 37) ( Table 1) . To examine whether disruption of ceramide glycosylation restores p53-dependent apoptosis, we treated NCI/ADR-RES cells with MBOasGCS to silence GCS and then tested cell response to doxorubicin. As shown in Fig. 1A , MBOasGCS treatments significantly increased cell response to doxorubicin, as suppressed GCS expression in dose-dependent fashion (Fig. S1A) (Fig. 1B) . Interestingly, silencing of GCS with MBO-asGCS sensitized p53-mutant cells, but not p53 wild-type cells. With decreases of GCS protein levels ( and Bax, as GCS was significantly suppressed in NCI/ADR-RES cells ( Fig. 2A) . Silencing of GCS by MBO-asGCS reactivated p53 response to doxorubicin-induced DNA damage, as pp53 levels were increased with decrease of GCS protein (Fig. 2B ). As expected, GCS protein levels were suppressed by MBO-asGCS in dose-dependent manner; the pp53 levels were significantly increased greater than 2-fold, even though at 50 nM MBO-asGCS, while unphosphorylated p53 protein levels were constant in all treatments (Fig. 2B) . Consequently, the levels of p21 increased nuclear pp53 in more than 90% of NCI/ADR-RES cells exposed to doxorubicin (Fig.   2C ). Different from wild-type p53 A2780 cells (left panel), pp53 particles were also detected in cytoplasm even though most pp53 were concentrated in nucleus of NCI/ADR-RES.
Disruption of ceramide glycosylation induced p53-dependent cell growth arrest and apoptosis in mutant p53 cells
To examine the effects of GCS silencing on p53-responsive genes, we further assessed cell division and apoptosis. Puma is a major p53-responsive gene involved in induced-apoptosis in response to DNA-damage and cleaved PARP (c-PARP) as well as active caspase-7 (a-Casp7) are effectors in p53-dependent apoptosis processing (38-39). We found that the protein levels of Puma were significantly increased in NCI/ADR-RES cells exposed to doxorubicin after MBOasGCS (Fig. 3A) . The levels of c-PARP and a-Casp7 were increased by 2-to 3-fold, respectively. Silencing of Puma with siRNA eliminated the effects of reactivated p53 on Puma, c-PARP and a-Casp7 (Fig. 3A) . Flow cytometry assays revealed that MBO-asGCS pretreatments significantly affected cell division and apoptotic cells. The numbers of G2/M phase cells that were under dividing and proliferation in histogram of flow cytometry significantly decreased with increasing concentrations of MBO-asGCS (50-200 nM); however, G1 phase cell numbers were increased by 2-fold, 3-fold and 5-fold, respectively (Fig. 3B, 3C ). Furthermore, flow cytometry detected that the numbers of G0/G1 phase cells that are under apoptosis were 3-fold (9.4% vs. 3.4% of total cells), 7-fold (24.8 % vs. 3.4% of total cells), and 15-fold (52.6 vs. 3.4% of total cells) at 50-200 nM MBO-asGCS pretreatment, as compared with vehicle control respectively. Silencing of Puma eliminated the apoptotic effects of restored p53 (Fig. 3B, 3D ). These data indicates that silencing of GCS resulted in cell growth arrest and apoptosis through p53-responsive genes.
Restoration of functional p53 expression induced apoptosis in mutant p53 tumors
We further investigated whether silencing of GCS restores p53 expression and eliminates mutant p53 tumor growth in vivo. After tumors of NCI/ADR-RES were apparent, mice were treated with MBO-asGCS (1 mg/kg twice a week, intratumoral injection) combined with doxorubicin (2 mg/kg once a week, i.p.) for 32 days. MBO-asGCS combined with doxorubicin decreased tumor volume to 42 % (157 mm Western blotting detected that silencing of GCS substantially decreased GCS, which in turn increased pp53 and p53-responsive genes in tumors exposed to doxorubicin (Fig. 4B) . MBOasGCS treatments increased wild-type p53, as represented by the ratio of pp53/p53 greater than 4-fold (p<0.001), as compared to vehicle control or MBO-SC. Consequently, the reactivated p53 substantially induced the expression of p21 Waf1/Cip1 , Bax, Puma and a-Casp7 (Fig. 4B ).
Immunostaining confirmed these findings and showed that MBO-asGCS, but not MBO-SC, significantly increased nuclear pp53 in tumors while decreased GCS protein in cytoplasm (Fig.   4C ). TUNEL analysis indicated that approximately 80% of tumor cells underwent apoptosis in tumors treated with MBO-asGCS combined with doxorubicin, compared to only 3% and 9% of apoptotic cells in doxorubicin alone and doxorubicin combined with MBO-SC (Fig. 4D) . Thus, these data indicate that GCS suppression restores wild-type p53 expression and leads mutant p53 tumors to induced-apoptosis. To determine whether ceramide or glucosylceramide after disruption of ceramide glycosylation is the factor restoring p53, we assessed its effects on cellular ceramide and glycosphingolipids. In NCI/ADR-RES cells, MBO-asGCS treatments (50-200 nM) decreased globotriaosylceramide (Gb3) and significantly increased ceramide (Fig. S2A ) in dosedepdendent fashion. At 200 nM of MBO-asGCS, endogenous ceramide increased more than 160% (1.01 vs. 1.65 ng/100 µg protein, p<0.001) (Fig. S2C) . Additionally, MBO-asGCS significantly enhanced ceramide in other p53 mutant OVCAR-8 and A2780ADR cells, but not p53 wild type cells (Fig. S2D) . Further, we examined the expression of pp53 and p53-responsive and Bax.
Ceramide mediated the restoration of p53 expression
Exogenous cell-permeable C6-ceramide (C6-Cer, 25 µM, 48 hr) substantially increased pp53 level by 9-fold; however, C6-dihydroceramide (C6-diH-Cer; 25 µM, 48 hr) that had less bioactivity enhanced pp53 by 2-fold and could not significantly increase p21 Waf1/Cip1 or Bax (Fig.   5A ). Immunofluorescent staining confirmed that MBO-asGCS dramatically increased cellular ceramide, and pp53 dramatically appeared in nucleus in cells exposed to doxorubicin (Fig. 5B ).
FB1 that inhibited ceramide synthase prevented cellular ceramide and pp53 reactivated in nucleus, even though MBO-asGCS disrupted ceramide glycosylation. C6-Cer treatment significantly increased pp53 in nucleus, as C6-Cer was detected mostly in cytoplasm and nuclear envelope (Fig. 5B) . 
To understand how silencing of GCS reactivates p53, we examined protein, mRNA and hnRNA of mutant p53 and wild-type p53 in cell lines that dominantly express wild-type 53 or mutant p53 after GCS silencing. As shown in Fig. S3A , MBO-asGCS pretreatment (50 nM, 7 days) did not significantly affect pp53 levels in MCF-12A and A2780 cells, as p53 expression in these wild-type p53 responded to doxorubicin exposure. In contrast, MBO-asGCS considerably increased pp53 by approximately 3-fold in mutant p53 OVCAR-8 and NCI/ADR-RES cells. The mRNA that included p53 exon-5 could not be detected in mutant p53 OVCAR-8 and NCI/ADR-RES cells, even under doxorubicin exposure (Fig. S3B) . However, we detected p53 exon-5 in mutant p53 cells after silencing of GCS with MBO-asGCS pretreatment (Fig. S3B) . Analysis of p53 hnRNA found that p53 exon-5 was transcribed in both wild-type and mutant p53 cell lines (Fig. S3C) . These data indicate that silencing GCS may restore p53 at the level of posttranscriptional processing. apoptosis, even though it does not significantly alter p53 protein levels, as reported previously (25) and detected by Western blotting in the present study ( Fig. 2A, 2B , 4B, 5A, S1A). However, further assessments unveil that the levels of pp53, p53-responsive genes (p21 Waf1/Cip1 , Bax, Puma), and apoptosis are all significantly increased in dose-dependent fashion (Fig. 2-4) . These evidences indicate that functional p53, but not mutant p53, is involved in DNA-damage inducedapoptosis after disruption of ceramide glycosylation. In particular type of cells, the direct effects of ceramide-activated mitochondrial alterations may be dominant. It is more likely that ceramide processing apoptosis is associated with p53-dependent pathways, as we have found that ceramide increased after MBO-asGCS treatment (Fig S2) (29) or exogenous C6-ceramide reactivates pp53 in nucleus and enhances p53-responsive genes including p21
Waf1/Cip1 , Bax and Puma (Fig. 2, 3, 4, 
5).
Mutant p53 is a defined target for cancer therapies; however, discovering an effective approach to restore functional p53 is a great challenge. Mutant p53 is often expressed at high levels in cancers, and it affects tumor progression and treatment outcome in terms of loss-offunction in tumor suppression as well as gain-of-function in oncogenic effects (12, 43) . On the other hand, peptide C361-382 restores the transcriptional activity of mutant p53 by an allosteric mechanism of negative regulation (44, 47) . In the present study, we have found that ceramide mediates p53 restoration, as silencing of GCS with MBO-asGCS can increase endogenous ceramide (29) and C6-ceramide leads to the same restorative effects (Fig. 2, 4, 5) .
It is not clear how ceramide restores functional p53 in deletion mutant of p53. In addition to direct effects on processing of apoptosis, ceramide mediates gene expressions including MDR1, telomerase, c-fos, p21
Waf1/Cip1
, GCS, caspase-9 and Bcl-x (34) (35) (48) (49) . Ceramide might reactivate functional p53 by modulating either mutant p53 conformation or wild-type p53 expression, but based on this study, it is more likely that ceramide restores wild-type p53 expression at posttranscriptional processing. Suppression of GCS restores p53 reactivation in 12 hr to several days ( Fig. 2A) , and wild-type p53 is detected in mRNA and protein (Fig. 2, 4 , 5, MBO-asGCS, a specific agent for GCS suppression effectively restores p53-dependent apoptosis in vitro and in vivo. Further investigating the association of GCS and mutant p53 in drug resistance and the molecular mechanism by which ceramide mediates p53 restoration in mutant p53-barrier cancers may lead to discovering effective approaches to improve cancer treatment. *also defined as A2780-DX3 that does not respond to CDDP-induced p53 activation, but mutation type has not been determined (32) . GCS mRNA was measured by real-time
RT-PCR (35).
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